Elanco Animal Health Inc (ELAN) stock
ELANNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 9/30129% above fair value
$26.70+0.85 (+3.29%)
Close on Nov 18, 2026Market cap $13.34BP/E –Yield –
Elanco Animal Health gross margin
Gross margin is gross profit as a percentage of revenue.
Elanco Animal Health's gross margin for the twelve months ending Jun 30, 2026 was 55.4%. For fiscal 2025 it was 55.0%, against 54.9% the year before. The highest annual figure on record is 56.6% in fiscal 2022.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 55.0% | +0.1 |
| FY2024 | Dec 31, 2024 | 54.9% | −1.4 |
| FY2023 | Dec 31, 2023 | 56.3% | −0.3 |
| FY2022 | Dec 31, 2022 | 56.6% | +1.4 |
| FY2021 | Dec 31, 2021 | 55.2% | +6.2 |
| FY2020 | Dec 31, 2020 | 49.0% | −3.1 |
| FY2019 | Dec 31, 2019 | 52.1% | +3.5 |
| FY2018 | Dec 31, 2018 | 48.7% | +0.4 |
| FY2017 | Dec 31, 2017 | 48.3% | −3.3 |
| FY2016 | Dec 31, 2016 | 51.6% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 58.3% | +0.9 |
| Q1 FY2026 | Mar 31, 2026 | 57.3% | −0.1 |
| Q4 FY2025 | Dec 31, 2025 | 51.5% | +0.6 |
| Q3 FY2025 | Sep 30, 2025 | 53.4% | +1.2 |
| Q2 FY2025 | Jun 30, 2025 | 57.5% | −0.7 |
| Q1 FY2025 | Mar 31, 2025 | 57.3% | +0.1 |
| Q4 FY2024 | Dec 31, 2024 | 50.9% | +0.7 |
| Q3 FY2024 | Sep 30, 2024 | 52.2% | −2.2 |
| Q2 FY2024 | Jun 30, 2024 | 58.2% | −0.7 |
| Q1 FY2024 | Mar 31, 2024 | 57.3% | −3.4 |
| Q4 FY2023 | Dec 31, 2023 | 50.1% | −4.4 |
| Q3 FY2023 | Sep 30, 2023 | 54.4% | +0.4 |
| Q2 FY2023 | Jun 30, 2023 | 58.9% | +0.1 |
| Q1 FY2023 | Mar 31, 2023 | 60.7% | +2.2 |
| Q4 FY2022 | Dec 31, 2022 | 54.5% | +0.4 |
| Q3 FY2022 | Sep 30, 2022 | 54.0% | −1.6 |
| Q2 FY2022 | Jun 30, 2022 | 58.8% | +1.9 |
| Q1 FY2022 | Mar 31, 2022 | 58.5% | +4.0 |
| Q4 FY2021 | Dec 31, 2021 | 54.1% | +6.4 |
| Q3 FY2021 | Sep 30, 2021 | 55.6% | +5.3 |
| Q2 FY2021 | Jun 30, 2021 | 56.9% | +7.4 |
| Q1 FY2021 | Mar 31, 2021 | 54.5% | +5.1 |
| Q4 FY2020 | Dec 31, 2020 | 47.7% | −0.2 |
| Q3 FY2020 | Sep 30, 2020 | 50.3% | −2.9 |
| Q2 FY2020 | Jun 30, 2020 | 49.5% | −5.0 |
| Q1 FY2020 | Mar 31, 2020 | 49.4% | −3.6 |
| Q4 FY2019 | Dec 31, 2019 | 47.9% | −0.5 |
| Q3 FY2019 | Sep 30, 2019 | 53.3% | +1.9 |
| Q2 FY2019 | Jun 30, 2019 | 54.5% | +10.5 |
| Q1 FY2019 | Mar 31, 2019 | 53.0% | +1.9 |
| Q4 FY2018 | Dec 31, 2018 | 48.4% | +2.1 |
| Q3 FY2018 | Sep 30, 2018 | 51.4% | +5.4 |
| Q2 FY2018 | Jun 30, 2018 | 44.0% | −5.0 |
| Q1 FY2018 | Mar 31, 2018 | 51.1% | −0.9 |
| Q4 FY2017 | Dec 31, 2017 | 46.3% | – |
| Q3 FY2017 | Sep 30, 2017 | 46.0% | – |
| Q2 FY2017 | Jun 30, 2017 | 49.0% | – |
| Q1 FY2017 | Mar 31, 2017 | 52.0% | – |
See a number that looks wrong?